$CAMP

CAMP4 Therapeutics (Nasdaq: CAMP) received UK authorization to include sites in its Phase 1/2 trial for CMP-002, a potential treatment for SYNGAP1-related disorder. The company plans to start the trial in 4Q 2026, following clearances in Australia and Argentina. CMP-002 aims to restore SYNGAP protein levels, with no approved therapies currently available for this rare disorder.

Gold Kelly (Chief Financial Officer) purchased 10,000 indirectly-held shares of Camp4 Therapeutics Corp (CAMP) at $3.96 on 2026-08-31.

Schwab Andrew J. sold 400,000 indirectly-held shares of Camp4 Therapeutics Corp (CAMP) at $4.04 ($1.62M total) on 2026-08-27.

Schwab Andrew J. sold 191,865 indirectly-held shares of Camp4 Therapeutics Corp (CAMP) at an average of $4.59 ($4.50–$4.76, $0.88M total) across 3 trades over 2026-08-19 to 2026-08-21.

Polaris-affiliated funds and individuals updated their ownership in Camp4 Therapeutics (CAMP) common stock, reporting a lower percentage due to dilution from new share sales. Polaris Management Co. VII now owns 4.8% (3,023,161 shares), while board member Amir Nashat owns 6.3% (3,932,251 shares). The amendment reflects changes since the prior filing.

CAMP4 Therapeutics (CAMP) reported Q2 2026 net loss of $33.5M, or $0.58/share, versus $12.6M, or $0.62/share, a year earlier. The wider loss was mainly due to a $20.9M non-cash derivative fair value change. R&D rose to $10.8M. CAMP4 received Australia and Argentina clearance for a Phase 1/2 CMP-002 trial, expected to start in Q4 2026, and raised $50.1M, extending runway to end-2028.

Camp4 Therapeutics Corp (CAMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth qua

Young Richard A purchased 16,378 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.

Maricich Yuri (Chief Medical Officer) purchased 6,551 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.

Gold Kelly (Chief Financial Officer) purchased 6,551 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.